Results 111 to 120 of about 22,196 (255)

Prolactinomas: evolution after menopause

open access: yesArchives of Endocrinology and Metabolism
Objetive The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause ...
Maria Susana Mallea-Gil   +20 more
doaj   +1 more source

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2010
Michael A Via1, Himani Chandra2, Takako Araki1, Matthew V Potenza3, Maria Skamagas41Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USA; 2Division of Endocrinology, Diabetes and ...
Via MA
doaj  

A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease

open access: yesMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2002
Background and Objective: Parkinson is a common disease that caused by degeneration of nigrostriatal dopaminergic pathways. Drug therapy can prevent movement disorders in patients and so they can do independently their daily activities.
A Ahmadi Ahangar, SAR Sadraei Mousavi
doaj  

Home - About - Disclaimer - Privacy